$5.27
-0.41-7.22%
Last update: Nov 5, 2:17 PM
Phathom Pharmaceuticals Inc (PHAT) Stock Price, Quote, News & History
PHATNASDAQ
Phathom Pharmaceuticals (NASDAQ: PHAT) reported Q4 sales of $57-$58 million, updated FY2025 revenue guidance to $174.5-$175.5 million.
You can purchase shares of Phathom Pharmaceuticals (NASDAQ:PHAT) through any online brokerage.
Other companies in Phathom Pharmaceuticals’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Phathom Pharmaceuticals has a consensus price target of $17.50.
The stock price for Phathom Pharmaceuticals (NASDAQ: PHAT) is $5.27 last updated November 5, 2026 at 2:17 PM EST.
There are no upcoming dividends for Phathom Pharmaceuticals.
Phathom Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Phathom Pharmaceuticals.
Phathom Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule...
